<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="134312">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01675479</url>
  </required_header>
  <id_info>
    <org_study_id>STAR-111IDHP</org_study_id>
    <nct_id>NCT01675479</nct_id>
  </id_info>
  <brief_title>Safety and Effectiveness of Wavefront-Guided LASIK Correction of Hyperopic Refractive Errors</brief_title>
  <official_title>A PROSPECTIVE STUDY TO EVALUATE THE SAFETY AND EFFECTIVENESS OF WAVEFRONT-GUIDED LASIK CORRECTION OF HYPEROPIC REFRACTIVE ERRORS WITH THE IDESIGN ADVANCED WAVESCAN STUDIO™ SYSTEM AND STAR S4 IR™ EXCIMER LASER SYSTEM</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Medical Optics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Medical Optics</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Demonstrate that wavefront-guided LASIK using measurements from the iDesign System is safe
      and effective for the treatment of Hyperopia.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">November 2015</completion_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Line loss for Best Spectacle Corrected Visual Acuity (BSCVA)</measure>
    <time_frame>9 Months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>&lt;5% of eyes with a loss of &gt; 2 lines of Best Spectacle Corrected Visual Acuity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Uncorrected Visual Acuity (VA) 20/40 or better</measure>
    <time_frame>9 Months</time_frame>
    <safety_issue>No</safety_issue>
    <description>85% of eyes with uncorrected visual acuity of 20/40 or better</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">145</enrollment>
  <condition>Hyperopia</condition>
  <arm_group>
    <arm_group_label>wavefront-guided LASIK</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>LASIK correction of hyperopic refractive errors</intervention_name>
    <description>Surgeons will perform wavefront-guided LASIK based upon measurement obtained with the iDesign System</description>
    <arm_group_label>wavefront-guided LASIK</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 18 years of age at the time of pre-operative exam

          -  Best Spectacle Corrected Visual Acuity (BSCVA) of 20/20 or better

          -  Demonstration of refractive stability

          -  Anticipated post-operative stromal bed thickness of at least 250 microns

          -  Willing and capable of returning for follow-up examinations for the duration of the
             study

        Exclusion Criteria:

          -  Women who are pregnant, breast-feeding, or intend to become pregnant over the course
             of the study

          -  Concurrent use of topical or systemic medications that may impair healing

          -  History of any medical conditions that could affect wound healing

          -  History of prior intraocular or corneal surgery, active ophthalmic disease, or other
             ocular abnormality

          -  Evidence of keratoconus, corneal irregularity, or abnormal topography in the
             operative eye(s)

          -  Known sensitivity or inappropriate responsiveness to any of the medications used in
             the post-operative course
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leonard Borrmann, PharmD</last_name>
    <role>Study Director</role>
    <affiliation>Abbott Medical Optics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kendra Hileman</last_name>
    <phone>714-247-8613</phone>
    <email>kendra.hileman@amo.abbott.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Maloney Vision Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Miami Bascom Palmer Eye Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kraff Eye Institute</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60602</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pepose Vision Institute</name>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <zip>63017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Coleman Vision</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Eye Center</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>King LASIK</name>
      <address>
        <city>Renton</city>
        <state>Washington</state>
        <zip>98057</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 11, 2014</lastchanged_date>
  <firstreceived_date>August 28, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>refractive</keyword>
  <keyword>errors</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hyperopia</mesh_term>
    <mesh_term>Refractive Errors</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
